Pliant Therapeutics, Inc.
NASDAQ:PLRXBiotechnology
-$0.04 today
- Market cap
- $50.14M
- Beta
- 1.21
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.83
Volume 0.15M
Average 0.49M
Returns on capital
Pliant Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-82.4%
avg 297.0%
ROIC
-71.4%
avg -96.6%
ROA
-66.3%
avg -67.2%
Analysis
ROA is currently the strongest return metric at -66.3% versus its period average of -67.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Bernard Coulie | President, Chief Executive Officer & Director | USD 938.9K | 60 | 0 | <0.01% |
Keith Lamont Cummings | Chief Financial Officer | USD 820.2K | 49 | 0 | <0.01% |
Minnie Kuo | Chief Operating Officer | USD 774.47K | 45 | 0 | <0.01% |
Dean Sheppard | Scientific Founder & Member of Scientific Advisory Board | — | — | — | — |
Hal Chapman | Scientific Founder & Member of Scientific Advisory Board | — | — | — | — |
Tim Machajewski | Senior VP & Head of Research | — | — | — | — |
Monica Sandberg | Vice President, Regulatory & Compliance | — | — | — | — |
Bill DeGrado | Scientific Founder | — | — | — | — |
Christopher S. Keenan | Vice President of Investor Relations & Corporate Communications | — | — | — | — |
Delphine Imbert | Chief Technical Officer | — | — | — | — |
Lily Cheung | Chief Human Resources Officer | — | 53 | 0 | <0.01% |
Daniel Park | Senior Vice President of Development Operations | — | — | — | — |
Scott Peters | Senior Vice President of Finance | — | — | — | — |
Rik Derynck | Scientific Founder & Member of Scientific Advisory Board | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Apr 17, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
4
$163,619.84
Net Transaction Value
−$163,619.84
Net selling
Most Active
Cummings Keith Lamont
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jan 20, 26Jan 20, 2026 | Cummings Keith Lamont Direct | Sell | $30.7K$30,722.56 |
| Jan 20, 26Jan 20, 2026 | Cheung Lily Direct | Sell | $9.6K$9,643.52 |
| Jan 20, 26Jan 20, 2026 | Coulie Bernard Direct | Sell | $114.4K$114,400.00 |
| Jan 20, 26Jan 20, 2026 | Kuo Minnie Direct | Sell | $8.9K$8,853.76 |
Summary
Insiders reported 0 buys worth $0.00 and 4 sells worth $163,619.84 over the last 12 months. That adds up to net selling of $163,619.84. Cummings Keith Lamont was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Pliant Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about PLRX's management, answered from reported figures.
Who manages PLRX?
Pliant Therapeutics, Inc. (PLRX) lists 14 active executives. The top listed executive is Bernard Coulie, President, Chief Executive Officer & Director.
Are PLRX insiders buying or selling?
Recent insider activity shows net selling of $22.94M.
Continue the stock analysis
Jump to another research area for this company.